Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-601 first-in-human pediatric study in GJB2-related congenital hearing loss
2026-525698-38-00Phase 2Authorised
- Sponsor
- Sensorion
- Start
- Oct 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label trial of SENS-601 in sensorineural hearing loss (SNHL) and autosomal recessive nonsyndromic deafness 1A (DFNB1A) (2 arms), sponsored by Sensorion. Primary endpoints: Treatment-emergent adverse events and device safety in Part 1 and Auditory response change in Part 2. Planned start Oct 2026; status: authorised.
02
Drugs
SENS-601
03
Conditions
sensorineural hearing loss (SNHL)autosomal recessive nonsyndromic deafness 1A (DFNB1A)
Beyond the preview
Go deeper on 2026-525698-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525698-38-00.